INTRODUCTION

Medical consensus increasingly points to the suitability of transition-related medical care and gender-affirming surgery for certain transgender or gender non-conforming (TGNC) patients. Surgery can be an important step following hormone therapy and counseling.1–3 Body image satisfaction, quality of life, and social functioning have been shown to improve for TGNC patients who are prepared for and choose to undergo gender-affirming surgery.4–11

The number of patients receiving gender-affirming genital surgery (GAGS) has increased in the past 2 decades.12 Whether the availability of GAGS meets demand remains unknown. If access to surgeons is insufficient nationally, regionally, or by state, subsets of the TGNC population may remain medically disadvantaged. In this study, GAGS availability and determinants of this availability were assessed. Although a variety of procedures may be performed for gender-affirmation, we chose to focus on vaginoplasty, metoidioplasty, and phalloplasty because of the unique demand for these services among TGNC patients, the complexity of these procedures, and the history of limited access in the United States.13

We hypothesized that federal and state healthcare legislation and prospective market sizes, may indicate strategies for overcoming disparities. (Plast Reconstr Surg Glob Open 2021;9:e3422; doi: 10.1097/GOX.0000000000003422; Published online 16 February 2021.)
care would predict the availability of GAGS. We additionally hypothesized that the size of states’ TGNC population would serve as an index for local demand and predict the availability of care.

**METHODS**

**Data Collection**

Eighteen databases of gender surgeons were discovered between November 2019 and January 2020 through Internet search. All sources were publicly available. Requirements for database inclusion were provision of names and practice locations for providers, as well as a date of publication (Fig. 1). Databases meeting inclusion criteria were lists of surgeons’ professional affiliations, such as the World Professional Association for Transgender Health (WPATH), a non-profit professional organization devoted to education around transgender health, as well as those from charitable and community organizations.

An initial list of 1055 gender surgeons was compiled. Of these, 377 were unique. All surgeons were subsequently verified through individual phone calls and detailed web reviews. A GAGS practice was defined by the presence of at least 1 surgeon offering vaginoplasty, metoidioplasty, or phalloplasty. This categorical definition followed from the fact that insurance-based legal discriminations against gender-affirming surgeries often have not distinguished between transfeminine and transmasculine surgeries, but have treated GAGS singularly. Surgeons who performed genital surgeries common to the general population, such as hysterectomy or oophorectomy, were excluded if they did not also perform vaginoplasty, metoidioplasty, or phalloplasty. Surgeons were excluded if they performed only non-genital gender-affirming surgeries, such as chest, neck, or facial reconstruction.

In 2014, the Department of Health and Human Services reversed a federal policy that had denied Medicare coverage for gender-affirming surgeries. To identify the possible impact of this policy reversal on the availability of GAGS, we conducted a second date-restricted Internet search. As with the 2019–2020 query, inclusion criteria for databases from the date-restricted search (January 2007–January 2014) were the provision of names, practice locations, and date of publication. Seven databases were discovered. Verifications of practice scope were conducted through cross-validation on multiple databases, and in many cases additionally through continued practice into 2019.

**Mapping**

Current and historical GAGS practices were mapped with QGIS 3.10 software. Inclusion zones of 100-mile radii encircled GAGS practices to identify states, regions, and large cities with access to local care. The availability of care was additionally described by population-to-practice ratios by state and region.

All legislative and demographic data were sourced secondarily. Legislative data were collected from the Movement Advancement Project in December 2019. MAP defines and tallies a standardized set of state healthcare policies dictating insurance coverage for gender-affirming care. Legislation was dichotomized as favorable or unfavorable based on a median split of 6 healthcare policies. Seven scores were possible. States with a summed score between 0 and 2 (inclusive) were deemed unfavorable to transgender health. Those with a score between 3 and 6 (inclusive) were deemed favorable. (See table, Supplemental Digital Content 1, which displays the “favorability” of state healthcare legislation toward coverage for gender-affirming care. A favorable legislative environment was hypothesized to increase the likelihood of a state having a GAGS practice.

TGNC demographic data, including estimated population sizes by state, were collected from the Williams Institute 2016 report. The Williams Institute uses modeling to estimate the size of TGNC populations. Although only a proportion of the TGNC population chooses to pursue GAGS, the size of state TGNC populations was taken as an index of demand. A threshold market size was defined as the minimum TGNC population necessary to support a GAGS practice in a state in 2019, and as a descriptive term, accounted for incomplete market capture. A preliminary approximation of this threshold was estimated by dividing the national TGNC population by the total number of GAGS practices in the United States in 2019. The resultant ratio was hypothesized and tested for significance as a minimum market size to support a single GAGS practice in any individual state. Sensitivity analysis was performed to estimate the effect of error in the initial derivation. The same cross-tabulations and chi-square analyses were performed 4 additional times, assuming that the originally derived market size was underestimated or overestimated by 25% or 50%. The threshold market size was the number of TGNC individuals that most consistently associated with the presence of a GAGS practice in a state in 2019.

**STATISTICAL TESTS**

Categorical availability of care, defined as the presence of at least 1 GAGS practice in a state, was used as the basis for testing correlations with legislation and market size. We used SPSS (IBM Corp. Released 2016. IBM SPSS Statistics for Windows, version 24.0. Armonk, N.Y.: IBM Corp.) to perform all cross-tabulations, 2-sided hypothesis tests, logistic regression modeling, and tests of interaction.

A binary logistic regression model was fit to assess the significance and independence of the legislation and market size variables as predictors of GAGS availability. To determine whether legislation moderated the relationship between local market size and GAGS availability, an interaction term was created using both the legislation and market size variables. A logistic regression model was fit with this interaction term as a predictor of GAGS availability.

**RESULTS**

GAGS was offered at 71 practices across the United States in 2019. These practices were distributed across 26 states and the District of Columbia. National disparities in the categorical availability of care were considerable,
as displayed graphically in the lower map of Figure 2 and regionally in Table 1. California had 16 GAGS practices, whereas 24 states did not have any. Thirty-five percent of the 113 cities in the United States with populations > 200,000 people did not have a GAGS practice within a 100-mile radius.

States of the Mideast and New England had the smallest (most favorable) ratio of GAGS practices-to-TGNC individuals: 1:10,772 and 1:11,880, respectively. The ratio was the highest (least favorable) in the States of the Southwest and Southeast: 1:37,200 and 1:47,706, respectively (Table 1).

In 2013, there were 34 GAGS practices distributed across 18 states. By 2019, there had been 209% growth in the number of GAGS practices in the United States, and 44% growth in the number of states with GAGS practices. This national growth followed a 2014 federal policy reversal, which banned public health insurance discrimination against gender-affirming surgeries.15

In 2019, state healthcare legislation that supported insurance coverage for gender-affirming care increased the odds of a state having a GAGS practice 4-fold when compared to states with unfavorable legislation (OR = 4.13, 95% C.I. 1.27–13.39; P = 0.016). Prospective state market sizes also significantly associated with the availability of care. A GAGS practice was 11-fold more likely to be present in a state where the local TGNC population surpassed 19,678 people (OR = 10.857, 95% C.I. 2.93–40.16; P < 0.001). Sensitivity analysis confirmed this market size to correctly predict the presence or absence of a GAGS practice in a state more often than did approximations 25% and 50% above or below this number. Market size...
did not significantly alter the probability of a state having favorable healthcare legislation ($P = 0.488$).

The logistic regression model including both the legislative and market size variables correctly predicted the availability of care in 76.5% of states. Legislation ($\text{OR} = 5.64; \text{C.I.} 1.28–24.79; P = 0.02$) and market size ($\text{OR} = 13.54; \text{C.I.} 3.07–59.68; P = 0.001$) were independently associated with GAGS availability. There was, however, an apparent interaction between the variables. A large market size appeared to moderate the association between healthcare legislation favorability and GAGS availability, as 100% of states with favorable legislation and a TGNC population above the threshold market size had a GAGS practice (Fig. 5). An interaction variable was modeled to assess the significance and directionality of this effect (Fig. 4).

The interaction proved significant ($P < 0.01$). Unfavorable legislation diminished the likelihood that

| Regional Divisions | States by Region                                                                 | Ratio of GAGS Practice to TGNC Population |
|--------------------|--------------------------------------------------------------------------------|------------------------------------------|
| Mideast            | Delaware, District of Columbia, Maryland, New Jersey, New York, and Pennsylvania | 1:10,772                                 |
| New England        | Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont     | 1:11,880                                 |
| Rocky Mountain     | Colorado, Idaho, Montana, Utah, and Wyoming                                     | 1:12,300                                 |
| Far West           | Alaska, California, Hawaii, Nevada, Oregon, and Washington                      | 1:14,742                                 |
| Plains             | Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota     | 1:17,617                                 |
| Great Lakes        | Illinois, Indiana, Michigan, Ohio, and Wisconsin                                | 1:18,817                                 |
| Southwest          | Arizona, New Mexico, Oklahoma, and Texas                                        | 1:37,200                                 |
| Southeast          | Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia | 1:47,706                                 |
a state with a TGNC population above the threshold market size had a GAGS practice. On the other hand, a small TGNC population restricted the beneficial effects of favorable legislation on ensuring local access to care: there were similar proportions of states with GAGS practices in the group with market sizes below the threshold, irrespective of whether healthcare legislation was favorable (Fig. 4).

**DISCUSSION**

Transgender and gender non-conforming individuals face multiple barriers to accessing healthcare in the United States. Insurance coverage has been unevenly distributed and often insufficient for this patient population. Despite recent improvements in coverage, stigmatization and inadequate provider-training in parts of the healthcare system continue to deter proper utilization and delivery.

The availability of GAGS, specifically phalloplasty, metoidioplasty, and vaginoplasty, and determinants of their availability were the focus of this study. Historically, access to GAGS has been limited in the United States. Demand is unique among TGNC patients. The procedures are highly complex and require dedicated training. The rate of GAGS performed in the United States has increased over the last 2 decades, yet regional availability of care has not been known.

We mapped disparities in the availability of GAGS by state and by region, and identified legal and market factors influencing access to care. Because in-depth services and volume data were not available, and because legal determinants of care availability often have treated GAGS singularly, GAGS practices were defined categorically. We demonstrated that significant disparities existed in access to GAGS across the United States in 2019 (Fig. 2, Table 1). Approximately 325,000 TGNC individuals lived in one of the 24 states without access to phalloplasty, metoidioplasty, or vaginoplasty services.

Where GAGS practices were available, access to care was often tenuously maintained. In 2019, 13 states had only 1 GAGS practice. Between 2013 and 2019, 4 states lost their only GAGS practice due to physician retirement or relocation. Sudden practice closures may be difficult to remediate because of the specialized training required for these procedures, typically following surgical residencies.

On a national scale, the apparent impact of supportive legislation on GAGS availability was seen in the doubling of GAGS practices in the United States between 2013 and 2019. This followed a 2014 federal policy revoking insurance exclusions for gender-affirming care.

Still, in 2019, local healthcare legislation and prospective market sizes independently predicted disparate access to GAGS by state. States with estimated TGNC populations greater than 19,678 people were nearly 11-fold more likely to have a GAGS practice of some kind. A TGNC population of this size increased the likelihood of GAGS availability in a state more than did healthcare legislation supporting insurance coverage for gender-affirming care. Market size may therefore have been a stronger determinant of access to care in 2019.
Small TGNC populations were likely to face disproportionate burden in accessing a GAGS practice, even if their state healthcare legislation was favorable toward gender-affirming care (Fig. 3). This phenomenon may have created additional hardship for those dwelling in isolated communities who were unable to travel for economic, professional, or social reasons.

Multiple recommendations may be considered on the basis of our findings. Clear geographic disparities existed in the availability of GAGS in 2019. TGNC individuals living in areas where the legal or demographic environment predicted limited access to GAGS may struggle to obtain healthcare that could enable them to function more successfully.9,47,48 The solution may be to increase the availability of local care, or to facilitate access to geographic “centers of excellence.”

Increasing the number of GAGS practices nationally might require maintaining providers and surgeons in low-volume environments. Incentives would be necessary to ensure public and private support where demand is low. In contrast, a centers of excellence approach might require improving patient mobility to ensure equitable access to care. Centers of excellence models have been proposed in an increasing number of fields, including surgical oncology,49 bariatric surgery,50 aortic cardiac surgery,51 and other specialties.52,53

**LIMITATIONS**

Every GAGS surgeon included in our mapping was individually verified by phone or web review, resolving an issue of database reliability discussed in previous work.54 This bottom-up approach made the research logistically feasible; however, it left open the possibility that the compilation was not exhaustive. The historical query may have overestimated the number of bottom surgeons available at the end of 2013, as some practices may have closed after databases were published. It would have been ideal to have volume and in-depth services data to better characterize access to care; however, this information was not available and is difficult to procure. It is important to understand which data are missing before formulating the next steps in ensuring access to care.

The focus on GAGS, to the exclusion of other important gender-affirming procedures, was chosen because of the unique demand for GAGS in the transgender and GNC population, and for reasons of historical inaccessibility. Variation in practice volume and services among GAGS practices, such as in the types of phalloplasty procedures offered, was not addressed by this study. A workforce study would provide additional information on availability of these services and possible differences in their use across the country, and granularity into possible disparities in the availability of different types of care.
In some cases, the correlation of legislation with the availability of care may be due to cultural-political environments that preceded policy itself. Additional studies looking at longitudinal effects of policies could potentially uncover causative forces. The possible impact of a pre-existing GAGS practice on the development of a large TGNc transgender population was beyond the scope of this study and immaterial to the question of a minimum market size necessary to support a GAGS practice. Many TGNc individuals choose not to undergo gender-affirming surgeries. Market size calculations are liable to change as finances, behaviors, and treatment options for gender-affirming care evolve.

Despite the limitations noted, our analysis provides a historical snapshot of access to GAGS in the United States in 2019, and of legislative and market forces predicting this access. As the availability of GAGS remains disparate, further research will be necessary to ensure equitable access to care.

Amir H. Taghinia, MD, MPH, MBA
Department of Plastic and Oral Surgery
Boston Children’s Hospital and Harvard Medical School
300 Longwood Avenue
Boston, MA 02115
E-mail: amir.taghinia@childrens.harvard.edu

REFERENCES

1. Boskey ER, Johnson JA, Harrison C, et al. Ethical issues considered when establishing a pediatrics gender surgery practice. Pediatrics. 2019;143:e20183053.
2. Owen-Smith AA, Gerth J, Sineath RC, et al. Association between gender confirmation treatments and perceived gender congruence, body image satisfaction, and mental health in a cohort of transgender individuals. J Sex Med. 2018;15:591–600.
3. Olson-Kennedy J, Warus J, Okonta V, et al. Chest reconstruction and chest dysphoria in transmasculine minors and young adults: Comparisons of nonsurgical and postsurgical cohorts. JAMA Pediatr. 2018;172:431–436.
4. Cardoso da Silva D, Schwarz K, Fontanari AMV, et al. WHOQOL-100 before and after sex reassignment surgery in Brazilian male-to-female transsexual individuals. J Sex Med. 2016;13:988–993.
5. de Vries AL, McGuire JK, Steensma TD, et al. Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics. 2014;134:696–704.
6. Mora E, Cobeta I, Becerra A, et al. Comparison of cricothyroid approximation and glottoplasty for surgical voice feminization in male-to-female transsexuals. Laryngoscope. 2018;128:2101–2109.
7. Papadopulos NA, Zašin D, Lellé JD, et al. Male-to-female sex reassignment surgery using the combined technique leads to improved quality of life in a prospective study. Plast Reconstr Surg. 2017;140:286–294.
8. Becker I, Auer M, Barkmann C, et al. A cross-sectional multicenter study of multidimensional body image in adolescents and adults with gender dysphoria before and after transition-related medical interventions. Arch Sex Behav. 2018;47:2335–2347.
9. van de Grift TC, Krekules BPC, Ellering I, et al. Body image in transmen: Multidimensional measurement and the effects of mastectomy. J Sex Med. 2016;13:1778–1786.
10. Weigert R, Frison E, Sessieqc Q, et al. Patient satisfaction with breasts and psychosocial, sexual, and physical well-being after breast augmentation in male-to-female transsexuals. Plast Reconstr Surg. 2013;132:1421–1429.
11. van de Grift TC, Pigot GLS, Boudhan S, et al. A longitudinal study of motivations before and psychosexual outcomes after genital gender-confirming surgery in transmen. J Sex Med. 2017;14:1622–1628.
12. Camner JK, Harfouch O, Kodakec LM, et al. Temporal trends in gender-affirming surgery among transgender patients in the United States. JAMA Surg. 2018;153:609–616.
13. Plemr E. A capable surgeon and a willing electorologist: Challenges to the expansion of transgender surgical care in the United States. Med Anthropol Q. 2019;33:282–301.
14. Green J. Transsexual surgery may be covered by Medicare. LGBT Health. 2014;1:256–258.
15. U.S. Department of Health & Human Services Departmental Appeals Board. NCD 140.3, Transsexual surgery, Docket No. A-13-87, Decision No. 2576 (2014). Published May 30, 2014. Available at https://www.hhs.gov/sites/default/files/static/dab/decisions/board-decisions/2014/dab2576.pdf. Accessed November 30, 2019.
16. Morrison SD, Satterwhite T. Lower jaw contouring in facial gender-affirming surgery. Facial Plast Surg Clin North Am. 2019;27:233–242.
17. Monstre E, Selvaggi G, Geulemans P, et al. Chest-wall contouring surgery in female-to-male transsexuals: A new algorithm. Plast Reconstr Surg. 2008;121:849–859.
18. Salgado C J, Nugent AG, Satterwaite T, et al. Gender reassignment: Feminization and masculinization of the neck. Clin Plast Surg. 2018;45:635–645.
19. Movement Advancement Project. State profiles: healthcare laws and policies. Published December 2019. Available at https://www.lgbtmap.org/equality_maps/. Accessed December 15, 2019.
20. Flores AR, Herman JL, Gates C, et al. How many adults identify as transgender in the united states? Available at https://williamsinstitute.law.ucla.edu/wp-content/uploads/Trans-Adults-US-Aug-2016.pdf. Published August 2016. Accessed December 15, 2019.
21. Gonzales G, Henning-Smith C. Barriers to care among transgender and gender nonconforming adults. Milbank Q. 2017;95:726–748.
22. Sandy J, Herman J, Rankin S, et al. The report of the 2015 U.S. Transgender Survey. 2016. Available at https://ncve.dspace-direct.org/handle/20.500.11990/1299. Published December 2016. Accessed November 15, 2019.
23. Glick JL, Andrinopoulos KM, Theall KP, et al. “Tiptoeing around the system”: Alternative healthcare navigation among gender minorities in New Orleans. Transgend Health. 2018;3:118–126.
24. Khan L. Transgender health at the crossroads: Legal norms, insurance markets, and the threat of healthcare reform. Yale J Health Policy Law Ethics. 2011;11:375–418.
25. Grant JM, Motter LA, Tanis J. Injustice at every turn: a report of the national transgender discrimination survey. Washington, D.C.: National Practice for Transgender Equality and National Gay and Lesbian Task Force; 2011. Available at https://data.princeton.edu/jspsi/handle/88435/dsp014j03d232p. Accessed December 15, 2019.
26. Conron KJ, Scott G, Stowell GS, et al. Transgender health in Massachusetts: Results from a household probability sample of adults. Am J Public Health. 2012;102:118–122.
27. White Hughto JM, Murchison GR, Clark K, et al. Geographic and individual differences in healthcare access for U.S. Transgender adults: A multilevel analysis. LGBT Health. 2016;3:424–433.
28. Dewey JM. Knowledge legitimacy: How trans-patient behavior supports and challenges current medical knowledge. Qual Health Res. 2008;18:1345–1355.
29. Reisner SL, Poteat T, Keatley J, et al. Global health burden and needs of transgender populations: A review. Lancet. 2016;388:412–436.
30. Berli JU, Knudson G, Fraser L, et al. What surgeons need to know about gender confirmation surgery when providing care for transgender individuals: A review. *JAMA Surg.* 2017;152:394–400.

31. Almazan AN, Benson TA, Boskey ER, et al. Associations between transgender exclusion prohibitions and insurance coverage of gender-affirming surgery. *LGBT Health.* 2020;7:254–263.

32. Padula WV, Heru S, Campbell JD. Societal implications of health insurance coverage for medically necessary services in the U.S. transgender population: A cost-effectiveness analysis. *J Gen Intern Med.* 2016;31:394–401.

33. Hughsto JMW, Reisner SL, Pachankis JE. Transgender stigma and health: A critical review of stigma determinants, mechanisms, and interventions. *Soc Sci Med.* 2015;147:222–231.

34. Reisner SL, Hughsto JM, Dunham EE, et al. Legal protections in public accommodations settings: A critical public health issue for transgender and gender-nonconforming people. *Milbank Q.* 2015;93:484–515.

35. Oben-Maliver J, Goldsmith ES, Stewart L, et al. Lesbian, gay, bisexual, and transgender-related content in undergraduate medical education. *JAMA.* 2011;306:971–977.

36. Learmonth C, Viloria R, Lambert C, et al. Barriers to insurance coverage for transgender patients. *Am J Obstet Gynecol.* 2018;219:272.e1–272.e4.

37. Stroumsa D, Wu JP. Welcoming transgender and nonbinary patients: Expanding the language of ‘women’s health. *Am J Obstet Gynecol.* 2018;219:585.e1–585.e5.

38. Nahata L, Quinn GP, Calzadilla NA, et al. Mental health concerns and insurance denials among transgender adolescents. *LGBT Health.* 2017;4:188–193.

39. Robles R, Fresán A, Vega-Ramírez H, et al. Removing transgender identity from the classification of mental disorders: A Mexican field study for ICD-11. *Lancet Psychiatry.* 2016;3:850–859.

40. Uhrig JD, Stryker JE, Breree S, et al. HIV infection needs of transgender people and their healthcare providers. *AIDS Care.* 2019;31:357–363.

41. Bradford J, Reisner SL, Honnold JA, et al. Experiences of transgender-related discrimination and implications for health: Results from the Virginia Transgender Health Initiative Study. *Am J Public Health.* 2013;103:1820–1829.

42. Van Donge N, Schney NA, Roberts TA, et al. Transgender dependent adolescents in the U.S. military health care system: Demographics, treatments sought, and health care service utilization. *Mil Med.* 2019;184:e447–e454.

43. Baker KE. The future of transgender coverage. *N Engl J Med.* 2017;376:1801–1804.

44. Tollinche LE, Walters CB, Radix A, et al. The perioperative care of the transgender patient. *Anesth Analg.* 2018;127:359–366.

45. Morrison SD, Dy GW, Chong HJ, et al. Transgender-related education in plastic surgery and urology residency programs. *J Grad Med Educ.* 2017;9:178–183.

46. Magoon KL, LaQuaglia R, Yang R, et al. The current state of gender-affirming surgery training in plastic surgery residency programs as reported by residency program directors. *Plast Reconstr Surg.* 2020;145:567–574.

47. Butler RM, Horenstein A, Gitlin M, et al. Social anxiety among transgender and gender nonconforming individuals: The role of gender-affirming medical interventions. *J Abnorm Psychol.* 2019;128:25–31.

48. Testa RJ, Rider GN, Haug NA, et al. Gender confirming medical interventions and eating disorder symptoms among transgender individuals. *Health Psychol.* 2017;36:927–936.

49. Wexner SD, Berho M. Commentary for establishing centers of excellence for surgical oncology. *Surg Oncol.* 2018;27:A2–A4.

50. Gallagher AG, Angelo RL, Kearney P. Factors associated with variation in outcomes in bariatric surgery centers of excellence. *JAMA.* 2018;320:1386–1387.

51. Gifford ED, de Virgilio C. Aortic centers of excellence: Shifting the focus. *JAMA Surg.* 2016;151:845.

52. Carvalho B, Mhyre JM. Centers of excellence for anesthesia care of obstetric patients. *Anesth Analg.* 2019;128:844–846.

53. Ghazal Asswad R, Harrison A, Hans PS, et al. Laryngeal ulceration in Behçet’s disease: The role of centres of excellence in the UK. *J Surg Case Rep.* 2019;2019:rjz017.

54. Cohen W, Maisner RS, Mansukhani PA. Barriers to finding a gender-affirming surgeon. *Aesthetic Plast Surg.* 2020;44:2300–2307.